R&D From phase 1 to phase 3: Scaling radiopharmaceutical trials Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.
Digital AI is exposing a new digital maturity divide in pharma busin... As AI adoption increases, it is exposing just how prepared organisations really are to operate in a digitally connected environment.
Sales & Marketing Headcount is not a growth strategy Deciding when, where, and how quickly to add headcount is rarely straightforward.
Patients Innovation can transform NHS care, but scaling is the missin... Innovation is already improving care across the NHS, but we are not yet consistently delivering at scale for the benefit of patients
R&D Looking ahead to 2026 in biopharma A look forward to trends to come in 2026, including AI-driven drug development, advanced modalities, and cardiometabolic disease therapies.
Market Access Why impactful and scalable global Medical Information (MI) p... A trusted MI partner ensures compliance with global and local regulations and provides consistent access to accurate medical information.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.